• Mon news: AZ obesity pill. 50% of drug shortages last at least 2 years. Pharmas and IRA lawsuit appeals. Novo-Ascendis biobucks deal. Wegovy reduces all-cause hospital admissions. See more on our front page

insulin

  1. Novo Nordisk reports first quarter results

    Novo Nordisk says pricing pressure within diabetes to continue, especially in the US. First quarter 2019 results: Sales from North America Operations declined 4% on constant exchange rates.
    • anonymous
    • Thread
    • biopharma diabetes gilead sciences insulin merck novo nordisk obesity pfizer pharmaceutical sanofi
    • Replies: 3
    • Forum: Novo Nordisk

  2. Upbeat performance in Q4

    Medtronic posted better-than-expected fourth quarter earnings. Earnings came in at $1.07 a share. Excluding items, the company earned $1.42, topping analysts’ estimate of $1.39. Revenue came in at $8.1 billion, meeting the consensus estimate of $8 billion. Strong global demand for the new...
    • anonymous
    • Thread
    • diabetes earnings insulin medtronic
    • Replies: 4
    • Forum: Medtronic

  3. Is Afrezza even that great?

    Seems like most who try it never refill it. Horrible retention numbers. Makes me believe the product isn’t as great as the shills on message boards/twitter make it out to be.
    • Steve Berger
    • Thread
    • afrezza diabetes insulin mannkind mnkd
    • Replies: 12
    • Forum: MannKind

  4. Dave Ricks hopes for a favorable tax reform

    Lilly expects to continue the investments in U.S., if favorable tax reform measures are enacted. Announces a $72 million investment in an insulin manufacturing project. http://alphastreet.com/b3264790
    • anonymous
    • Thread
    • diabetes eli lilly indianapolis insulin manufacturing
    • Replies: 0
    • Forum: Eli Lilly
Top Bottom
Back